Table 3 Patients’ disposition based on COVID-19 severity.
Variable | Severe COVID-19 (n = 151) | Nonsevere COVID-19 (n = 39) | p |
|---|---|---|---|
Age | |||
≥65 years (%) | 112 (74.2) | 17 (43.6) | <0.05 |
<65 years (%) | 39 (25.8) | 22 (56.4) | |
Gender | |||
Male (%) | 98 (64.9) | 28 (71.8) | n.s. |
Female (%) | 53 (35.1) | 11 (28.2) | |
Median time between CLL diagnosis and COVID-19 | 88 | 71 | n.s. |
Treatment for CLL | |||
Untreated (%) | 64 (42.7) | 9 (23.1) | <0.05 |
Treated (%) | 86 (57.3) | 30 (76.9) | |
Treatment during the last 12 months or ongoing | |||
Yes (%) | 60 (39.7) | 24 (61.5) | <0.05 |
Untreated or treated > 12 months before (%) | 91 (60.3) | 15 (38.5) | |
Treatment | |||
1 previous line (%) | 48 (31.8) | 14 (35.9) | n.s. |
2 or more previous lines (%) | 38 (25.2) | 16 (41.0) | |
Comorbidities | |||
>2 | 46 (30.5) | 12 (30.8) | n.s. |
≤2 | 105 (69.5) | 27 (69.2) | |
Hypogammalobulinemia | |||
Yes | 66 (55.0) | 23 (67.6) | n.s. |
No | 54 (45.0) | 11 (32.4) | |
Outcome | |||
Alive (%) | 96 (63.6) | 37 (97.4) | <0.00001 |
Dead (%) | 55 (36.4) | 1 (2.6) | |
